Table 1.

Clinicopathologic characteristics of 2 population-based prostate cancer patient cohorts

Seattle cohort (n = 1,309)Swedish cohort (n = 2,875)
Age at diagnosis, y
Follow-up time, y
Prostate cancer-specific death
Age at death, y
Gleason score
Diagnostic PSA level, ng/mL
 < 417813.61485.1
 ≥ 201189.01,00334.9
Primary therapy
 Radical prostatectomy77058.871324.8
 Radiation therapy35927.468223.7
 Androgen deprivation614.792732.2
  • aIncludes men who died of other causes and were censored at time of death (Seattle, n = 102; Sweden, n = 258).